John Libbey Eurotext

Hépato-Gastro & Oncologie Digestive

MENU

IBD highlights at CREGG 2022 Volume 30, issue 2, February 2023

Figures


  • Figure 1
Author
Hôpital Henri-Mondor, AP-HP, Service de gastro-entérologie, 1 rue Gustave Eiffel, 94000 Créteil
* Correspondance : M. Uzzan

Clinical research in IBD is currently booming leading to the advent of new medical treatments with novel mechanisms of action. Many progresses are also being made for a more comprehensive clinical management of patients with the ultimate goal of improving the quality of life of patients with inflammatory bowel diseases (IBD). The holistic approach to take care of patients with IBD can include specific dietary interventions as well as physical activity and psychologic managements. Digital solutions are also being developed to support holistic care of patients. Additionally, recent news about JAK inhibitors have been presented during the CREGG (Club de Réflexion des Cabinets et Groupes d’Hépato-Gastroentérologie) conference, notably highlighting new safety recommendations by regulating agencies. Finally, data were presented about the sequencing of biologics and small molecules, which is a hot topic with many parameters to consider to adopt the best sequence of treatments for a specific patient.